Neuheit Pharma Technologies Profile
Key Indicators
- Authorised Capital ₹ 4.90 Cr
as on 16-12-2024
- Paid Up Capital ₹ 2.93 Cr
as on 16-12-2024
- Company Age 11 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -8.46%
(FY 2022)
- Profit -92.20%
(FY 2022)
- Ebitda -76.56%
(FY 2022)
- Net Worth -27.75%
(FY 2022)
- Total Assets -36.30%
(FY 2022)
About Neuheit Pharma Technologies
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.90 Cr and a paid-up capital of Rs 2.93 Cr, as per Ministry of Corporate Affairs (MCA) records.
Venkateswarlu Vobalaboina and Vamshi Vobalaboina serve as directors at the Company.
- CIN/LLPIN
U24232TG2013PTC089826
- Company No.
089826
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Sep 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Neuheit Pharma Technologies?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkateswarlu Vobalaboina  | Managing Director | 03-Sep-2013 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vamshi Vobalaboina | Director | 14-Sep-2020 | Current |
Financial Performance of Neuheit Pharma Technologies.
Neuheit Pharma Technologies Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 8.46% decrease. The company also saw a substantial fall in profitability, with a 92.2% decrease in profit. The company's net worth observed a substantial decline by a decrease of 27.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neuheit Pharma Technologies?
In 2022, Neuheit Pharma Technologies had a promoter holding of 84.47% and a public holding of 15.53%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Atindriya Solutions LlpActive 3 years 1 monthVenkateswarlu Vobalaboina and Vamshi Vobalaboina are mutual person
- Sri Rama Surya Constructions Private LimitedActive 3 years 3 months
Vamshi Vobalaboina is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Neuheit Pharma Technologies?
Neuheit Pharma Technologies has a workforce of 45 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neuheit Pharma Technologies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neuheit Pharma Technologies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
